14.08.2016 • NewsAstraZenecaElaine BurridgeModerna

AstraZeneca Ups Stake in Moderna Therapeutics

AstraZeneca has invested another $140 million in US biotech concern Moderna Therapeutics. The new investment is part of a preferred-stock financing and lifts its stake in Moderna to 9%. Moderna’s knowhow is being used to develop drugs based on messenger ribonucleic acid (mRNA) which helps create proteins inside cells, offering a new way of tackling diseases that are hard to treat with existing therapies.

The British-Swedish drugmaker first invested in Moderna in March 2013 to access its expertise for developing mRNA medicines for cardiovascular, metabolic and renal diseases, as well as oncology. A further agreement made in January 2016 focuses on developing cancer treatments. Moderna has two Phase I studies underway for mRNA-based infectious disease vaccines. Last month, AstraZeneca and Moderna filed for approval in Germany to run another Phase I clinical trial of a vascular disease treatment.

Cambridge, Massachusetts-based Moderna also has strategic agreements in place with Alexion Pharmaceuticals, US Merck and Vertex Pharmaceuticals. The firm has so far raised more than $1.2 billion in cash to fund its efforts.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.